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ABSTRACT: Anticancer nanomedicine-based multimodal imaging and
synergistic therapy hold great promise in cancer diagnosis and therapy
owing to their abilities to improve therapeutic efficiency and reduce
unnecessary side effects, producing promising clinical prospects. Herein, we
integrated chemotherapeutic drug camptothecin (CPT) and near-infrared-
absorbing new indocyanine green (IR820) into a single system by charge
interaction and obtained a tumor-microenvironment-activatable PCPTSS/
IR820 nanoreactor to perform thermal/fluorescence/photoacoustic-imaging-
guided chemotherapy and photothermal therapy simultaneously. Specifically,
the generated PCPTSS/IR820 showed an excellent therapeutic agent loading
content and size stability, and the trials in vitro and in vivo suggested that the
smart PCPTSS/IR820 could deeply permeate into tumor tissues due to its
suitable micellar size. Upon near-infrared laser irradiation, the nanoreactor further produced a terrific synergism of chemo−
photo treatment for cancer therapy. Therefore, the PCPTSS/IR820 polyprodrug-based nanoreactor holds outstanding promise
for multimodal imaging and combined dual therapy.
KEYWORDS: tumor microenvironment, polyprodrugs, chemotherapy, phototherapy, multimodal imaging
1. INTRODUCTION
The multiformity, complicacy, and heterogeneity of cancer
immensely limit the efficiency of conventional cancer
therapies.1 Nowadays, detection of and curing cancer and
entering into the cancer-free world are the biggest challenges
we are facing. The approaches for cancer treatment in the
clinic are embracing chemotherapy, surgery, ultrasound
therapy and radiotherapy,2−5 photothermal therapy
(PTT),6−8 photodynamic therapy (PDT),9,10 gene therapy,11
and other treatments, which have been proved to be effective.
However, the long-term retention in the early stage of a clinical
study is an insurmountable barrier to overcome, and more
remarkable techniques are hankeringly launched and applied in
cancer treatment. Among them, PTT is a noninvasive
approach, which can induce cell death by transforming light
into heat. Numerous PTT agents including near-infrared
(NIR)-absorbing organic dyes,12,13 gold nanostructures,14−16
carbon dots,17 carbon nanotubes,18 and graphene19 have been
reported, but all of them have confirmed that PTT can be
served as a local therapy strategy and is invalid for the distant
tumor cells. It is a fact that single therapy modality is unable to
eliminate the tumor thoroughly owing to the generation of
multidrug resistance.20 To resolve these barriers, the concept
of “multimodal synergistic therapy (MST)” was pre-
sented,21−23 and multimodal strategy based on several
therapeutic modalities can effectively inhibit tumor growth
with fewer side effects.24−26 The realization of MST is not a
simple mix but an integration of different therapeutic
modalities by nanotechnology,27 in which nanomaterials
reach tumor sites in a manner of active or passive targeting28,29
and further realize cancer diagnosis and therapy.
Compared with a normal physiological environment, a
tumor microenvironment (TME) is distinctive and featured
with mildly acidic conditions (pH 5.0−6.5),30−32 high
concentration of glutathione (GSH),33 overexpressed matrix
metalloproteinases,34 hypoxia (<5 mm Hg),35 high reactive
oxygen species (ROS) levels,36,37 and so on. In accordance
with these obvious differences, nanomaterials can be endowed
with the response function upon intrinsic or extrinsic stimuli to
deliver curing agents to the region of infraction. Above all, the
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design and preparation of TME-responsive nanomedicines
based on MST are essential, and a number of relevant
achievements have been established frequently. For example,
Luan et al. integrated new indocyanine green (IR820) and
paclitaxel (PTX) into one system and obtained a pH and
enzyme dual-responsive carrier to realize chemo−photo-
thermal therapy, and the in vitro and in vivo results suggested
that the IR820-PTX nanoparticle could effectively eliminate
tumor cells by chemo-PTT dual therapy.38 In 2018, Xie’s
group utilized red blood cell membranes to encapsulate a
chemotherapeutic agent PTX and a photosensitizer 5-(4-
carboxyphenyl)-10,15,20-triphenyl-chlorin for the preparation
of ROS-responsive nanoparticles. The treatment efficiency of
photodynamic therapy (PDT) and chemotherapy could be
simultaneously triggered using a 638 nm laser lamp, showing
enhanced systematic toxicity.39 However, the ability of existing
strategies against tumors may be limited by lower tumor
permeation and accumulation, a slower response to tumor
cells, etc. Thus, more high-performance strategies deserve to
be established and translated into the clinic.
Herein, we designed and constructed a TME-responsive
nanoreactor PCPTSS/IR820 for synergistic chemo-PTT
(Scheme 1). In brief, a polyprodrug of β-CD-PCPTSS-NH2
(marked as PCPTSS) was prepared, which can form water-
soluble unimolecular micelles with a strong positive charge
feature. Then, new indocyanine green (IR820)40,41 with a
negative charge was introduced into the PCPTSS micelles with
the assistance of the dimethyl sulfoxide (DMSO) solvent.
Finally, the formation process of PCPTSS/IR820 could be
driven by the charge interaction between PCPTSS and IR820,
producing a multimodal-imaging-guided chemotherapy and
photothermal therapy (PTT) nanoreactor. This designed
strategy resolved the short lifetime of IR820 and the poor
solubility of camptothecin (CPT) and exhibited high CPT and
IR820 content (11.12 and 27.8 wt %, respectively). Specifically,
the high-density disulfide bond could effectively consume
intracellular GSH, which could improve the therapeutic
efficiency.42,43 In addition, the obtained nanoparticles
presented fine characteristics including excellent biocompati-
bility, admirable stability, outstanding photothermal stability,
praiseworthy antiphotobleaching capacity, and enhanced
tumor permeation ability, which promoted PCPTSS/IR820 as
a prominent nanomedicine for multimodal imaging [photo-
thermal imaging, NIR imaging, and photoacoustic (PA)
imaging] and combined dual therapy (chemotherapy and
PTT).
2. EXPERIMENTAL SECTION
2.1. Materials. All chemicals were obtained from Sigma-Aldrich
unless otherwise noted. All bioreagents were supplied by Life
Technologies (China), including penicillin streptomycin mixture
(PS), phosphate-buffered saline (PBS, 1×, pH = 7.4), Dulbecco’s
modified Eagle’s medium (DMEM), fetal bovine serum, TrypLE
Express Enzyme (1×), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) cell viability reagent, LysoTracker Red
(LysoTracker), Alexa Fluor488 phalloidin (AF-488), and the Live/
Dead viability kit. Ultrapure water was prepared by a Milli-Q Plus
system.
2.2. Synthesis of 2-((tert-Butoxycarbonyl)amino)ethyl
Methacrylate (MMEA). Specifically, ethanol amine (10 mmol) and
di-tert-butyl dicarbonate (10 mmol) were dissolved in 30 mL of
acetonitrile and stirred for 15 min. The solvent was then removed by
evaporation, and the intermediate tert-butyl-N-(2-hydroxyethyl)
carbamate was obtained. Next, the intermediate (62 mmol) and
N,N-diisopropylethylamine (93 mmol) were dissolved in 100 mL of
dichloromethane (DCM), and methacryloyl chloride (68 mmol) was
dropwise added and the mixture was stirred at room temperature
overnight. The final product was purified by silica column
chromatography (eluent: DCM and hexane, volume/volume =
1:10) and was denoted MMEA.
2.3. Synthesis of β-CD-P(CPT-co-MMEA-co-OEGMA). The
CPT monomers (CPTSS and CPTCC) and macroinitiator (β-CD-
Br) were synthesized according to our previous report,44 and the
detailed information is illustrated in the Supporting Information. The
chains of the starburst polyprodrug named β-CD-P(CPT-co-MMEA-
Scheme 1. Schematic Illustration of the PCPTSS/IR820 Nanoreactor for Combined-Therapy-Based Enhanced Chemotherapy/
Phototherapya
a(A) The chemical structures of PCPTSS prodrug and IR820. (B) The assembly mechanism of the PCPTSS/IR820 nanoreactor based on the
interaction effect of the positive/negative charge, self-assembly process, and therapeutic mechanism of the PCPTSS/IR820 nanoreactor in vivo.
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co-OEGMA) (denoted PCPT-BOC) were synthesized using the
following atom transfer radical polymerization process: we added β-
CD-Br (0.001 mmol), copper(I) bromide (0.021 mmol), CPTSS or
CPTCC (0.21 mmol), 2-((tert-butoxycarbonyl)amino)ethyl methacry-
late (MMEA, 0.1 mmol), poly(ethylene glycol) methacrylate
(OEGMA, average Mn = 500, 0.8 mmol), anhydrous N,N-
dimethylformamide (DMF, 1.5 mL), and dimethyl sulfoxide
(DMSO, 1.5 mL) into a 15 mL Schlenk tube under a glovebox.
Next, the sample was degassed two times by liquid nitrogen. After
that, tris[2-(dimethylamino)ethyl]amine (0.021 mmol) was injected
and the polymerization was carried out for 24 h. Once the reaction
was finished, we mixed diethyl and dichloromethane to purify the
product three times. Then, we obtained the crude product PCPTSS-
BOC and PCPTCC-BOC. After a deprotection process of the t-
butyloxy carbonyl group using trifluoroacetic acid, the final product β-
CD-PCPTSS-NH2 (marked as PCPTSS) was obtained. The polymer
with a nonresponsive bond (marked as PCPTCC) was also synthesized
by the similar method.
2.4. Preparation of PCPTSS and PCPTSS/IR820 Micelles. First,
we dissolved the PCPTSS prodrug (10.0 mg) in the DMF solvent (5
mL) and stirred it constantly for 1 h to form PCPTSS micelles in an
organic solution (2.0 mg/mL). Next, we employed a dialysis method
to form PCPTSS in aqueous medium: the PCPTSS prodrug (10.0 mg)
totally dissolved in the DMF solvent (1.0 mL). Then, the solution was
added into the deionized water (10.0 mL) dropwise with constant
stirring. After that, the obtained sample was dialyzed against the
deionized water for the removal of the residual organic solvent.
Finally, we obtained the PCPTSS micelles in aqueous medium.
Similarly, we obtained the PCPTSS/IR820 in aqueous medium by the
following dialysis method: the PCPTSS prodrug (15 mg), IR820 (5
mg), and triethylamine (10 μL) were dissolved in DMF (1.0 mL) for
2 h, and the solution was added into the deionized water (10.0 mL)
dropwise with constant stirring for 1 h. Finally, the obtained sample
was dialyzed against the deionized water for the removal of the
residual organic solvent and we obtained the PCPTSS/IR820 micelles
in aqueous medium.
2.5. CPT Release from PCPTSS and PCPTCC Micelles. The drug
(CPT) release experiment in vitro on PCPTSS and PCPTCC was
carried on by dialysis using PBS solution with different dithiothreitol
(DTT) concentrations (0, 2 μM, 2 mM, and 10 mM) at the
temperature of 37 ± 1 °C. PCPTSS and PCPTCC micelles (1.0 mL)
were added into containers that contained the PBS solution (80 mL)
with different DTT concentrations. Next, we took out 1.0 mL of the
external solution according to a timing order. Finally, a fluorescence
calibration curve of CPT was pictured and the cumulative drug
(CPT) release of PCPTSS and PCPTCC was calculated according to it.
2.6. Cytotoxicity Assay. The in vitro cell viabilities of PCPTSS,
PCPTSS/IR820, and PCPTCC/IR820 micelles against 4T1 and
HepG2 cell lines were determined by MTT assays. Briefly, 5 × 103
cells for each well were preseeded in 96-well plates. Next, the cells
were cultivated in fresh culture medium of free CPT, free IR820,
PCPTSS, PCPTSS/IR820, and PCPTCC/IR820 with known concen-
trations. After incubation for 4 h, the cells treated with free IR820,
PCPTSS/IR820, and PCPTCC/IR820 were washed once and
irradiated with an 808 nm laser. After a 20 h incubation, the MTT
agent was added for a further 4 h incubation, and the results were
detected by a Tecan Spark-10 plate reader at 490 nm.
2.7. Cell Apoptosis Study. In brief, 4T1 or HepG2 cells were
cultivated in 12-well plates at the temperature of 37 °C. Then, the
cells were treated with free CPT, PCPTSS, PCPTSS/IR820, and
PCPTSS/IR820 and a laser in DMEM medium with CPT (5 μg/mL)
for 24 h. After being washed and diluted by PBS (1×) and binding
buffer (100 μL), respectively, we orderly added Annexin V-FITC (5
μL) and PI (1 μL) in the binding buffer. Finally, all cells were
detected by flow cytometry (NovoCyte 2060R). For the Live/Dead
study, 4T1 cells were added into 12-well plates and cultured for 24 h
with free CPT, PCPTSS, PCPTSS/IR820, and PCPTSS/IR820 with a
laser. After that, we stained the 4T1 cells with Calcein-AM and
propidium iodide (PI). A fluorescence microscope (Olympus, IX73)
was used to observe and obtain the result.
2.8. Fluorescence Imaging Study. First, 4T1 and HepG2 cells
were cultured in 8-well plates at about 2 × 104 cells for each well at
the temperature of 37 °C. After a confluence process, PCPTSS and
PCPTSS/IR820 micelles in DMEM containing CPT (12.5 μg/mL)
were added. The medium in each well was discarded and washed
using PBS (1×). Then, we added a formalin solution and incubated
them for 30 min. After that, we employed AF-488 for the staining of
cell membranes and LysoTracker Red for lysosomes. The lasers with
405, 488, 633, and 631 nm wavelengths were employed to,
respectively, excite CPT, AF-488, IR820, and LysoTracker Red. The
fluorescence images were observed and recorded by a confocal
microscope (Zeiss 800, Germany).
2.9. Cellular Uptake Study. In brief, 4T1 cells were cultured in
6-well plates at the temperature of 37 °C. After that, PCPTSS/IR820
micelles in DMEM medium containing IR820 (30 μg/mL) were
added. Then, the cells were cultured for different times. Next, each
well in plates was washed using PBS (1×) and the TrypLE Express
Enzyme (1.0 mL) was added to digest the cells. After a 3 min
centrifugation, we used the flow cytometry method to detect the
suspension. The fluorescence intensity of PCPTSS/IR820 was
determined using an APC channel. We regarded the cells without
any drug treatment as controls.
2.10. Multicellular Spheroid Study. To prepare 4T1 multi-
cellular spheroids (MCSs), 4T1 cells with a density of 1 × 103 were
added in 96-well plates with a certain amount of gelose. After
incubation at 37 °C for 3 days, the multicellular spheroids were
obtained and divided into two groups: PCPTSS/IR820 with GSH and
PCPTSS/IR820 without GSH. The CPT prodrug with DMEM was
co-incubated with MCSs for 6 h. After a washing process, the samples
were analyzed by confocal laser scanning microscopy (CLSM) (Zeiss
800).
2.11. Animal Model Establishment. The animal research in this
study was permitted by the Institutional Animal Care and Use
Committee (IACUC) of Southwest University. We purchased BALB/
c nude mice (5- or 6-week old, female, about 18−20 g) and Kunming
(KM) mice (6-week old, about 28−30 g) from the Academy of
Military Medical Sciences in Beijing, China. For the establishment of
the tumor model of female nude mice, we subcutaneously injected
about 5 × 106 of 4T1 cells in the DMEM medium (125 μL) into the
right axilla of mice. About 10 days after the injection, the tumor
volumes increased to around 100 mm3 and the female nude mice
could be used for in vivo tests.
2.12. Blood Testing. We used an injection method to evaluate
the biosafety in vivo of PCPTSS and PCPTSS/IR820 micelles
(injection quantity: 5 mg/kg). First, we randomly divided the
Kunming mice into three groups with three mice for each group.
Next, we injected PBS (200 μL), PCPTSS, or PCPTSS/IR820 micelles
(200 μL, 5 mg/kg, CPT equivalent) into the tail vein of mice. After 24
h of the injection, we collected and detected the KM mice blood (500
μL) using a hematology analyzer (Mindray BC-2600Vet).
2.13. In Vivo and ex Vivo Fluorescence Imaging. Free IR820
and PCPTSS/IR820 solutions (both IR820 dose of 1.0 mg/kg) were
injected into the tail veins of nude mice that bore xenograft 4T1
tumors using a microinjector. After 3, 6, 12, and 24 h of the injection,
we took the mouse body optical images using a NIR imaging system
(PerkinElmer IVIS Lumina Kinetic Series III). Finally, we dissected
the mice and took out the tumors and the normal organs, which were
used for ex vivo optical imaging afterward.
2.14. In Vivo PA Imaging. Free IR820 and PCPTSS/IR820
solutions (both IR820 dose of 1.0 mg/kg) were injected into the tail
veins of nude mice that bore xenograft 4T1 tumors using a
microinjector. After 3, 6, 12, and 24 h of the injection, we took the
optical images of the tumors using a PA imaging system (Endra Nexus
128 scanner).
2.15. In Vivo Thermal Imaging. PBS, PCPTSS, and PCPTSS/
IR820 solutions (both IR820 dose of 1.0 mg/kg) were injected into
the tail veins of nude mice that bore xenograft 4T1 tumors using a
microinjector. After 24 h of the injection, we took the mouse body
optical images using a thermal imager (PerkinElmer IVIS Lumina
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Kinetic Series III) and monitored the temperature of the tumor at
different illumination times.
2.16. Depth of the Penetration Experiment of PCPTSS/
IR820. IR820 or PCPTSS/IR820 (both IR820 dose of 2.0 mg/kg) was
injected into the tail veins of nude mice that bore xenograft 4T1
tumors using a microinjector. After 24 h of the injection, we dissected
the mice and the tumors were treated with 4% paraformaldehyde
solution, paraffined, and sliced into 5 μm thickness. Finally, we stained
the tumor slices with 4′,6-diamidino-2-phenylindole (DAPI) and
observed them by CLSM.
2.17. In Vivo Therapeutic Assay. We evaluated the in vivo
therapeutic efficacies of PCPTSS and PCPTSS/IR820 micelles by
measuring and recording the tumor volumes for 11 successive days.
We divided randomly the 4T1 tumor-bearing mice (∼20 g each) into
four groups (five mice per group) and marked them as “PBS”,
“PCPTSS”, “PCPTSS/IR820”, and “PCPTSS/IR820 + laser”. Then, 200
μL of PBS, PCPTSS, or PCPTSS/IR820 solutions with CPT (1.0 mg/
mL) was injected into the mice by the tail vein every three days.
Particularly, 24 h after the first injection, the PCPTSS/IR820 + laser
group was irradiated (808 nm, 1.8 W/cm2, 8 min). We measured and
recorded the tumor volumes and body weights of mice throughout
the whole therapeutic period. We calculated the tumor volume using
the following equation: volume = (length × width2)/2.
2.18. Histological Study. Besides chemotherapy, we also carried
out the histological study. We dissected the mice and took out the
tumors, hearts, livers, lungs, spleens, and kidneys. Then, we treated
the tumors and the organs with paraformaldehyde solution (4%) and
paraffined and sliced them into 5 μm thickness. Next, we stained the
tumor slices using hematoxylin and eosin (H&E) and terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assays. We employed a fluorescence microscope (Olympus, IX73) to
observe and take the fluorescent images.
2.19. Data Analysis. The method of t-test analysis of variance was
used to determine the statistical significance of the experimental
results. All data are shown as mean ± standard deviation (SD).
3. RESULTS AND DISCUSSION
3.1. Construction and Characterization of the PCPTSS/
IR820 Nanoreactor. Before the construction of the PCPTSS/
IR820 nanoreactor, we first synthesized a starburst polypro-
drug of PCPTSS, and the synthetic process is described in
Figure S1. The involved monomer and polyprodrug derivatives
were synthesized and characterized by 1H NMR and gel
permeation chromatography analysis (Figures S2−S5, Support-
ing Information). To build the multifunctional nanomedicine,
we further attached a commercial IR820 dye onto PCPTSS
micelles by electrostatic interaction. To verify the successful
formation of PCPTSS and PCPTSS/IR820 micelles, we first
studied the optical properties of representative materials using
absorption (Shimadzu UV-1800) and fluorescence (Shimadzu
RF-5301PC) spectra (Figure 1A,B). After an assembly process,
the representative absorbances of both CPT and IR820 were
present in the micelles of PCPTSS/IR820, demonstrating the
successful incorporation of PCPTSS and IR820. Subsequently,
the morphology and hydrodynamic radius were first recorded
by transmission electron microscopy (TEM, JEM-1230EX)
and dynamic light scattering (DLS, Malvern BI-200SM). As
shown in Figures 1C−E and S6, the adhesion of IR820 enabled
Figure 1. (A) UV−vis spectra of free CPT, CPTSS, PCPTSS, IR820, and PCPTSS/IR820 in DMF or water. (B) Fluorescence spectra of free CPT,
CPTSS, and PCPTSS in DMF or water. TEM images and optical images of (C) PCPTSS micelles and (D) PCPTSS/IR820 micelles. (E) DLS result
of PCPTSS/IR820 micelles in water. (F) ζ-potential results of free IR820, PCPTSS, PCPTSS/IR820, and PCPTSS/IR820 with the laser. (G) Mean
diameter distribution of PCPTSS and PCPTSS/IR820 micelle under different incubation times. (H) Temperature increase profiles of PBS, PCPTSS,
and PCPTSS/IR820 at different concentrations (0.05, 0.10, and 0.25 mg/mL) with NIR irradiation (808 nm, 1.8 W/cm
2, and 8 min); inset:
photothermal images of the solution recorded by an IR camera at the final temperature. (I) Temperature increase profiles of PCPTSS/IR820
aqueous solution upon NIR laser irradiation with different power densities (concentration of PCPTSS/IR820: 0.25 mg/mL) for 8 min.
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an obvious increase of hydrodynamic radius up to 51.39 nm for
PCPTSS/IR820. Nevertheless, the size was compatible for
prolonged circulation and deep permeation of tumor tissues.45
Obviously, the dispersion indexes of the two nanoparticles
were very low, indicating that the diameters of the prepared
micelles were homogeneous. The TEM imaging demonstrated
that both PCPTSS and PCPTSS/IR820 micelles had well-
defined spherical morphologies and diameters of around 21.9
and 46.4 nm, respectively. The sizes measured by DLS were
larger than those by TEM. The differences were due to the
hydration effect of micelles.46 We also studied the particle size
of PCPTSS micelles in water and DMF, as presented in Figure
S6, which could suggest the feature of unimolecular micelles
for PCPTSS micelles.
To support the formation mechanism of PCPTSS/IR820, the
ζ-potentials of free IR820, PCPTSS, PCPTSS/IR820, and
PCPTSS/IR820 + laser were recorded, and the results were
−47.1, +19.43, −5.5, and −3.23 mV (Figure 1F), respectively.
Due to the existence of a sulfonic acid group, the free IR820
showed a negative charge of −47.1 mV, whereas for PCPTSS, a
positive charge of +19.43 mV could be recorded because of an
amino group in the structure of PCPTSS. As such, the PCPTSS/
IR820 nanoreactor could be formed by a charge interaction.
The stability of nanoparticles was an important parameter for
the applicability as drug carriers. After a two-week storage, the
diameter variations of PCPTSS and PCPTSS/IR820 micelles
showed nonobvious fluctuations (Figure 1G). To improve the
therapeutic effect, negative or neutral nanoparticles were
deemed to be preferential candidates for prolonging the
blood circulation of nanoparticles. Otherwise, the nano-
particles with positive charges were easily cleared by the
reticuloendothelial system. Therefrom, we deemed that the
negative charged PCPTSS/IR820 nanoreactor was a promising
nanoparticle to promote the therapeutic effect.
Figure 2. In vitro release of CPT from (A) PCPTSS micelles and (B) PCPTCC micelles under different DTT concentrations. (C) Cell viabilities of
4T1 cells after incubation with different concentrations of free IR820 + laser, PCPTCC/IR820 + laser, PCPTSS/IR820, and PCPTSS/IR820 + laser
at the power density of 1.8 W/cm2 for 8 min for 24 h. (D) Cell viabilities of 4T1 cells after incubation with different concentrations of free CPT,
PCPTSS, and PCPTCC/IR820 for 24 h. (E) Cell viabilities of 4T1 cells incubated with PCPTSS/IR820 micelles (equivalent 820 concentration of 20
μg/mL, equivalent CPT concentration of 8 μg/mL) after 808 nm laser irradiation at different power densities for 8 min. (F) Summary data of cell
apoptosis. (G) Cell apoptosis results of 4T1 cells cultured with free CPT, PCPTSS, and PCPTSS/IR820 without and with the laser with CPT
concentrations of 5 μg/mL for 24 h. (H) Fluorescence images of 4T1 cells cultivated with PBS, free CPT, PCPTSS, and PCPTSS/IR820 without
and with the laser for 24 h (final equivalent CPT concentration: 5 μg/mL). The fluorescences of Calcein-AM (live cells) and PI (dead cells) were
stained as green and red, respectively. Scale bars: 200 μm. Error bars were based on the standard error of the mean (n = 3).
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The photothermal conversion performance is vital for PTT
therapy. We quantitatively testified the temperature variation
of PCPTSS/IR820 micelles with 808 nm NIR irradiation (1.8
W/cm2) for different concentrations. As seen in Figure 1H, the
temperature of PCPTSS/IR820 micelles increased very fast
primitively and a plateau was recorded after 8 min of
irradiation. The ultimate temperature was related to the
concentration of PCPTSS/IR820, and the temperatures of PBS
solution and PCPTSS micelles increased only about 1.3 and 3.6
°C within 8 min. We further detected the temperature
variation of PCPTSS/IR820 micelles upon NIR laser irradiation
with different power densities for 8 min. As depicted in Figure
1I, PCPTSS/IR820 showed a temperature change over different
irradiation times and irradiation power densities. In addition,
we evaluated the antiphotobleaching characteristic of PCPTSS/
IR820 and plotted temperature as a function of time (Figure
S7). PCPTSS/IR820 micelles (0.25 mg/mL) were heated and
cooled for three cycles, and the loss of the photothermal
conversion ability of PCPTSS/IR820 could be neglected. After
heating the PCPTSS/IR820 micelles for 8 min with an 808 nm
laser, we cooled down the samples to room temperature
naturally. These consequences provide sufficient evidence that
PCPTSS/IR820 has outstanding photothermal stability and
antiphotobleaching capacity.
3.2. In Vitro Reduction-Responsive Drug Release and
Cytotoxicity Assessment. Initially, the CPT release
tendencies were recorded from PCPTSS and PCPTCC micelles
in buffers with different DTT concentrations (0, 2 μmol, 2
mmol, and 10 mmol), which corresponded to the simulation
environment of blood plasma and tumor tissues. As shown in
Figure 2A,B, after 1 mL of PCPTCC micelles was dialyzed
against PBS with DTT for 48 h, the maximal release
percentage of CPT from PCPTCC micelles was only 6.6%
after the continuous culture in buffer (10 mM DTT) with a
period of 48 h, whereas 62.7 and 86.0% of cumulative CPT
were released from PCPTSS under the condition of 2 or 10
mmol DTT. Together, the release results demonstrated that
the reductive tumor microenvironment could cleave the
disulfide bond of PCPTSS and further release CPT. The
behavior suggested that the designed nanoparticles had almost
no immature drug release in a normal physiological environ-
ment.
To study the anticancer performance of all nanoparticles, we
first evaluated the in vitro cytotoxicity with different methods.
MTT results of 4T1 and HepG2 cell line proliferation
following free CPT, PCPTSS, PCPTCC/IR820, PCPTSS/
IR820, IR820 + laser, PCPTCC/IR820 + laser, and PCPTSS/
IR820 + laser micelle incubation with or without the 808 nm
laser exposure are depicted in Figures 2C−E and S8. All
samples showed a concentration-dependent capacity to induce
cancer cell death. PCPTSS/IR820 micelles with a laser
(PCPTSS/IR820 + laser) exhibited stronger capacity than
free IR820 + laser, PCPTSS/IR820, and PCPTCC/IR820 +
laser. For instance, as for 20 μg/mL IR820 of different drug
Figure 3. (A) CLSM images of 4T1 cells after treatment with PCPTSS/IR820 micelles with a CPT equivalent amount of 12.5 μg/mL and an IR820
equivalent amount of 30 μg/mL for 1, 2, and 6 h. The fluorescences of CPT, IR820, and AF-488 are marked as blue, red, and green, respectively.
(B) Lysosomal co-localization of 4T1 cells incubated with PCPTSS (CPT: 12.5 μg/mL) for 1, 2, and 6 h. Scale bars: 50 μm. (C) Flow cytometry
analysis of the intracellular uptake of micelles with an IR820 equivalent amount of 30 μg/mL in 4T1 cells incubated for 0, 1, 2, and 6 h (D) Mean
fluorescence intensity of PCPTSS/IR820 at various time points. The data is shown as mean ± SD (n = 3). (E) 4T1 cell microsphere experiment of
PCPTSS/IR820 with and without GSH (10 mM) treatment for 24 h. Scale bars: 100 μm.
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formulations that interacted with 4T1 cell lines for 4 h and
were irradiated with a 808 nm laser (1.8 W/cm2) for 8 min, the
cell viabilities of free IR820 + laser, PCPTSS/IR820, PCPTCC/
IR820 + laser, and PCPTSS/IR820 + laser were about 5.60,
67.08, 18.59, and 0.26% for the largest concentration,
respectively. Although free IR820 + laser had a favorable
antitumor ability in vitro, its short lifetime seriously affected its
antitumor ability in vivo. The prominent antitumor efficiency
of PCPTSS/IR820 + laser was related to the enhancement of
the cellular uptake efficiency and synergetic chemo−photo-
thermal therapy. We further investigated the cell viabilities of
4T1 and HepG2 cells incubated with identical concentrations
of PCPTSS/IR820 micelles (the concentration of IR820 was 20
μg/mL) after irradiation with different power densities for 8
min.
Next, we used the Annexin V-FITC/PI method to
quantitatively analyze the apoptosis caused by free CPT,
PCPTSS, PCPTSS/IR820, and PCPTSS/IR820 + laser at
different stages by flow cytometry; the results are shown in
Figure 2F,G (4T1 cell lines) and Figure S9 (HepG2 cell lines).
After being treated for 24 h, PCPTSS/IR820 + laser caused the
apoptosis of cells by up to 53.48%, which was higher than that
of the other three prodrugs. The consequence demonstrated
that PCPTSS/IR820 + laser had a splendid cytotoxicity for
cancer cells. Furthermore, Calcein-AM and PI were utilized to
stain live and dead cells, respectively, and the result was
recorded by a fluorescence microscope. Figure 2H presents
consistent results with the aforementioned trials. We could
conclude that combining chemotherapy and photothermal
therapy into one system had admirable antitumor properties.
3.3. Intracellular Uptake and Distribution of Micelles.
Fluorescent cell imaging was carried out by confocal
microscopy to analyze cellular uptake behavior and intra-
cellular distribution. 4T1 and HepG2 cell lines were also
adopted. After being interacted with PCPTSS/IR820 or
PCPTSS micelles for 1, 2, and 6 h, the cell membrane and
lysosome were stained with AF-488 or AF-633 and
LysoTracker Red dielectric fluid, respectively. Figures 3A,B
and S10−S12 show that the fluorescence intensity of IR820
from PCPTSS/IR820 micelles or CPT from PCPTSS and
PCPTSS/IR820 micelles increased gradually over time,
indicating that the cellular uptake efficiency of PCPTSS/
IR820 and PCPTSS micelles was time dependent. We verified
this by flow cytometry analysis, Figures 3C,D and S13 present
the quantitative cellular uptake efficiency of PCPTSS/IR820
micelles after incubation for 1 h (64.2%, MFI = 16829), 2 h
(88.9%, MFI = 27839), and 6 h (98.20%, MFI = 53989). This
phenomenon was attributed to the moderate diameter.
To assess the penetration ability of PCPTSS/IR820 micelles
in tumor tissues, we prepared 4T1 multicellular spheroids and
treated them with PCPTSS/IR820 with/without 10 mM GSH.
Figure 3E shows that the fluorescences of CPT and IR820
from PCPTSS/IR820 micelles without GSH are primarily
distributed on the margin of the MCSs, whereas the MCSs
cultivated with PCPTSS/IR820 micelles with GSH had a
noteworthy fluorescence intensity in the deep region of the
MCSs. The obvious fluorescence distribution differences could
be attributed to the decomposition of PCPTSS/IR820 micelles,
and small drug molecules of CPT and IR820 could be liberated
from micelles. The results showed a high tumor penetration
capacity and an enhanced therapeutic effect.
Figure 4. (A) In vivo NIR fluorescence imaging of nude mice with 4T1 tumors upon injection of free IR820 and PCPTSS/IR820 by the tail vein for
3, 6, 12, and 24 h. The tumor mean fluorescence intensity treated with (B) IR820 and (C) PCPTSS/IR820. (D) Ex vivo fluorescence imaging of
major organs and tumors 24 h after injection. (E) Relative fluorescence intensity of tumors and major organs (**P < 0.01). (F) In vivo PA imaging
of nude mice with 4T1 tumors upon injection of free IR820 and PCPTSS/IR820 by the tail vein for 3, 6, 12, and 24 h. The PA intensity of tumors
upon injection of (G) free IR820 and (H) PCPTSS/IR820 by the tail vein for 3, 6, 12, and 24 h. (I) Relative PA intensity values of tumors treated
with IR820 and PCPTSS/IR820.
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3.4. In Vivo Biodistribution. Subsequently, we used 4T1
tumor-bearing mice to explore the PCPTSS/IR820 micelle
biodistribution in vivo. After intravenous injection with free
IR820 and PCPTSS/IR820, the fluorescent imaging of the
whole body at different time points (3, 6, 12, and 24 h) was
carried out and is presented in Figure 4A. The fluorescence
intensity of IR820 from PCPTSS/IR820 accumulated in tumors
with a tendency of a distinct increase over time and peaked at
24 h (Figure 4B,C). Ulteriorly, as shown in Figure 4D,E, the
fluorescent images of tumors, hearts, livers, spleens, lungs, and
kidneys ex vivo also manifested that PCPTSS/IR820 micelles
had a long retention time at tumor sites, whereas free IR820
was mainly distributed at livers. This might be concerned with
the enhanced EPR effect of PCPTSS/IR820.
Before and after the injection of 1.0 mg/kg IR820 of free
IR820 and PCPTSS/IR820 by the tail vein, we detected the
photoacoustic signal of the tumor site. Figure 4F shows the
obtained photoacoustic (PA) imaging, and Figure 4G,H shows
the PA signal of each group at designated time intervals (3, 6,
12, and 24 h). Before free IR820 or PCPTSS/IR820 injection,
there was a feeble PA signal, which might be due to the
endogenous hemoglobin and melanin assimilated by the NIR
laser.47 After being administered for 24 h, the PCPTSS/IR820
group showed the maximum PA signal, which was 10.43 times
as much as the preinjection (Figure 4I), indicating that the
optimum time for photothermal therapy and PA imaging was
24 h after the injection.
3.5. In Vivo Combinational Therapy of Photothermal/
Chemotherapy. The in vivo therapeutic plan is shown in
Figure 5. In vivo antitumor performance with chemotherapy and photothermal therapy (808 nm, 1.8 W/cm2, 8 min) in the 4T1 tumor model. (A)
Representative photos of mice bearing 4T1 tumors after different treatments including PBS, PCPTSS, and PCPTSS/IR820 with laser irradiation. (B)
In vivo tumor temperature changes plotted against time for PBS, PCPTSS, and PCPTSS/IR820 with laser irradiation. (C) In vivo tumor temperature
change values with laser irradiation. (D) Changes in 4T1 tumor volumes were monitored every other day. (E) Body weight variation of nude mice
was monitored every other day. (F) Excised tumor weight. (G) Photograph of nude mice of every group. (H) Excised tumor photograph. (I) 24 h
following iv injection, the excised tumors were developed into frost slices and then the IR820 fluorescence distribution in entire tumors was
revealed by CLSM observation. (J) H&E staining images of the tumor and TUNEL staining images of the tumor after different treatments for 11
days.
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Figure 5A. Before in vivo experiments, we first evaluated the
photothermal imaging of PCPTSS/IR820 in vivo. The 4T1
tumor-bearing nude mice treated with PBS and PCPTSS were
used as comparable groups. After ceaseless irradiation with an
808 nm laser, there was a minor temperature variation in PBS
and PCPTSS groups, as shown in Figure 5B. However, the
tumor of mice administered PCPTSS/IR820 micelles showed a
temperature buildup as the exposure time increased. The
temperature variations against irradiation time curves are
plotted in Figure 5C. After irradiation for 8 min, the
temperature of PCPTSS/IR820 groups reached 56.6 °C (ΔT
= 20), whereas those of PBS and PCPTSS groups increased to
41.6 °C (ΔT = 7.3) and 40.9 °C (ΔT = 3.9), respectively. The
photothermal conversion performance was in accordance with
the PA conversion property.
The promising consequences mentioned above inspired us
to further study the synergistic effect of chemotherapy and
photothermal therapy of PCPTSS/IR820 with a xenograft 4T1
tumor-bearing mice model. Hereon, we focused on PBS,
PCPTSS, PCPTSS/IR820, and PCPTSS/IR820 + laser four
groups. After the first injection for 24 h, the tumors of
PCPTSS/IR820 + laser group mice were irradiated with an 808
nm (1.8 W/cm2) NIR laser for 8 min. Figure 5D−F shows the
changes of the tumor volume, mice body weight, and tumor
weight of excised tumors over time within the therapeutic
duration. The tumor volume of the PCPTSS/IR820 + laser
group was the smallest, and the eventual tumor volume was
19.91 mm3, whereas that of the control group went up to
850.54 mm3. The four groups showed similar changes in the
body weight. Before and after the treatment, the photographs
of mice and excised tumors were taken and are presented in
Figure 5G,H. Similarly, the PCPTSS/IR820 + laser group
showed the lightest tumor weight. The tumor inhibitory rates
of PCPTSS, PCPTSS/IR820, and PCPTSS/IR820 + laser were
68.00, 62.16, and 97.66% (Figure S14), respectively. Therefore,
we concluded that compared with PCPTSS, PCPTSS/IR820
micelles have a better anticancer effect.
We further evaluated the drug distribution of PCPTSS/
IR820 micelles in vivo. To be specific, 4T1 tumor-bearing
nude mice were injected with IR820 or PCPTSS/IR820. After
24 h, the tumors were excised for slices and then the cell nuclei
were stained with DAPI and observed by CLSM. As shown in
Figure 5I, compared with free IR820, PCPTSS/IR820 micelles
Figure 6. (A) In vivo blood test including red blood cells, heme regulation, and white blood cell count of healthy KM mice injected with saline,
PCPTSS, and PCPTSS/IR820 for 24 h. (B) H&E staining images of major organs after different treatments for 11 days. The scale bars of H&E
staining images were 50 μm.
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could enter into the depth of the tumor, which verified that
PCPTSS/IR820 had an outstanding tumor penetration ability.
Furthermore, the H&E and TUNEL stainings were used to
study the side toxicity of PCPTSS/IR820 in vivo. At the end of
the treatment, the tumors, hearts, livers, spleens, lungs, and
kidneys of each group were excised and sliced for H&E and
TUNEL stainings. Previous research indicated that the
necrosis of cells could lead to the cell membrane to be
incomplete or vanished, and the nucleus would burst or
condense. The H&E and TUNEL images in Figure 5J
suggested that there was no distinct cell necrosis in the PBS
group, and the tumors of PCPTSS, PCPTSS/IR820, and
PCPTSS/IR820 + laser showed different levels of cell necrosis.
3.6. In Vivo Safety and Histology Analyses. Next, we
also investigated the in vivo side effects of PCPTSS and
PCPTSS/IR820 micelles. Typically, 5 mg/kg CPT were
injected into healthy Kunming mice. After 24 h, the blood of
mice with prodrugs or normal saline administered was
gathered and analyzed. The homologous complete blood
count parameters including white blood cells, red blood cells,
hemoglobin, hematocrit, lymphocyte ratio, platelets, red cell
distribution width, and mean corpuscular hemoglobin
concentration in Figure 6A illustrated that there were no
statistical discrepancies in these representative counts between
PCPTSS or PCPTSS/IR820 micelles and control groups. The
results confirmed that these drug-treated groups caused a
negligible toxicity in mice and could serve as suitable
candidates for tumor therapy. Furthermore, after the in vivo
therapeutic effect, the H&E results further indicated that the
major organs showed neglected tissue damage (Figure 6B),
suggesting an outstanding in vivo safety.
4. CONCLUSIONS
In conclusion, a multifunctional and powerful nanoreactor that
can realize tumor-specific drug release and temperature
increments was prepared for multimodal-imaging-medicated
chemo/photothermal combination therapy. The obtained
PCPTSS/IR820 manifested the nanosized diameter and flexible
assembly based on electrostatic interaction, which endowed
the nanoreactor with an outstanding tumor permeability in
vitro and in vivo. Besides, it can further produce timely
reduction-triggered drug release and broad distribution of drug
molecules including CPT and IR820, resulting in remarkable
chemotherapy and photothermal therapy. Taken together, the
design of PCPTSS/IR820 provided an ingenious strategy for
the construction of smart nanomedicines for the tumor-specific
chemo/photothermal combination therapy.
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